MRA Expense Raises Doubts At FDA, Fuels Debate On Voluntary Status
This article was originally published in The Gray Sheet
Certification of European Union conformity assessment bodies under the U.S./EU mutual recognition agreement could require FDA Office of Compliance expenditures of $18 mil., according to rough estimates provided by OC official Kim Trautman at the Food and Drug Law Institute's 42nd Annual Educational Conference Dec. 17.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.